Evidence map›Paper›PMID 36541715›Full record

ArticleBiometrical journal. Biometrische Zeitschrift2024

Analysis of survival data with nonproportional hazards: A comparison of propensity-score-weighted methods.

Elizabeth A Handorf, Marc C Smaldone, Sujana Movva, Nandita Mitra

Abstract read
In one paragraph

Article in Biometrical journal. Biometrische Zeitschrift, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elizabeth A HandorfBiostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-0445-8978
Marc C SmaldoneDepartment of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Sujana MovvaDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Nandita MitraDivision of Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
TUFCCC/HC Regional Comprehensive Cancer Health PartnershipU54CA221705 · NCI · TEMPLE UNIV OF THE COMMONWEALTH · PI Joel Erblich, Jennifer S Ford · 2018 to 2026
$16.3M
NCI NIH HHS P30 CA006927NCI NIH HHS P30CA006927NCI NIH HHS P30 CA008748NCI NIH HHS U54 CA221705NCI NIH HHS U54CA221705
6 · The paper itself

Abstract

One of the most common ways researchers compare cancer survival outcomes across treatments from observational data is using Cox regression. This model depends on its underlying assumption of proportional hazards, but in some real-world cases, such as when comparing different classes of cancer therapies, substantial violations may occur. In this situation, researchers have several alternative methods to choose from, including Cox models with time-varying hazard ratios; parametric accelerated failure time models; Kaplan-Meier curves; and pseudo-observations. It is unclear which of these models are likely to perform best in practice. To fill this gap in the literature, we perform a neutral comparison study of candidate approaches. We examine clinically meaningful outcome measures that can be computed and directly compared across each method, namely, survival probability at time T, median survival, and restricted mean survival. To adjust for differences between treatment groups, we use inverse probability of treatment weighting based on the propensity score. We conduct simulation studies under a range of scenarios, and determine the biases, coverages, and standard errors of the average treatment effects for each method. We then demonstrate the use of these approaches using two published observational studies of survival after cancer treatment. The first examines chemotherapy in sarcoma, which has a late treatment effect (i.e., similar survival initially, but after 2 years the chemotherapy group shows a benefit). The other study is a comparison of surgical techniques for kidney cancer, where survival differences are attenuated over time.

Indexed as

Propensity ScoreComputer SimulationProportional Hazards ModelsSurvival Analysisinverse probability of treatment weightingnonproportional hazardsobservational studies

Identifiers

PMID36541715
PMCPMC10282107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.